CIT Appoints Bernard Galat VP of Business Development, North America Company
CIT,
a European non-clinical CRO, announced the opening of its new U.S. subsidiary, CITox, Inc. The new company is based in Boston, Massachusetts, and will spearhead CIT’s planned expansion of its U.S. activities.
CIT simultaneously announced the appointment of Bernard Galat, 55, as Vice-President Business Development, North America. Galat is a U.S. citizen and will be based in the Boston office.
The U.S. represents 15 per cent of CIT’s current sales today, and the company aims to increase this to 30 per cent in three to five years.
“CIT is also pleased to introduce Bernard Galat and announce this key appointment as a further indication of our continued customer centric growth,” said Baratte.
Prior to joining CIT, Galat held senior sales and marketing positions with Xceleron Inc., Parexel International and Carestat, Inc. Formerly, he served as Vice President of Sales, Marketing and Clinical Applications for Ultracision, Inc. There, he recruited, trained and managed a global sales force and led cross-functional teams to establish priorities for new product development. Johnson & Johnson acquired Ultracision for a multiple equal to ten times sales.
Galat received a BS magna cum laude from Northeastern University in Biology and Communications and earned an MBA with honors from Northeastern’s Graduate School of Business.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
